Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company’s web site at www.accentia.net.
- 17 years ago
QualityStocks
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – RedCloud Holdings plc (NASDAQ: RCT) to Participate in ROTH 15th Annual London Conference
RedCloud Holdings (NASDAQ: RCT) announced that CEO and Co-Founder Justin Floyd will attend the ROTH…
-
ONAR Holding Corp. (ONAR) Takes the Lead in AI-Driven Marketing as CEO Shares Vision
ONAR’s core focus is to accelerate revenue for middle-market companies via AI technology, innovation and…
-
FAVO Capital Inc. (FAVO): Aligning for Growth in a Booming Alternative Lending Market
FAVO recently secured an $8 million equity investment to fund growth and accelerate its plan…